Abstract
Vosaroxin is a quinolone compound that intercalates DNA and induces TP53-independent apoptosis, demonstrating activity against acute myeloid leukemia (AML) in Phase I-III trials. Here, we examine vosaroxin's mechanism of action and pharmacology, and we review its use in AML to date, focusing on details of individual clinical trials. Most recently, when combined with cytarabine in a randomized Phase III trial (VALOR), vosaroxin improved outcomes versus cytarabine alone for relapsed/refractory AML in patients older than 60 years and for patients in early relapse. We consider its continued role in the context of a multifaceted strategy against AML, including its current use in clinical trials. Prospective use will define its role in the evolving landscape of AML therapy.
Original language | English (US) |
---|---|
Pages (from-to) | 125-133 |
Number of pages | 9 |
Journal | Future Oncology |
Volume | 13 |
Issue number | 2 |
DOIs | |
State | Published - Jan 2017 |
Keywords
- acute myeloid leukemia
- antineoplastic agents
- intercalating agents
- prospective studies
- vosaroxin
ASJC Scopus subject areas
- Oncology
- Cancer Research